643 related articles for article (PubMed ID: 16846802)
1. Hit discovery and hit-to-lead approaches.
Keseru GM; Makara GM
Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
[TBL] [Abstract][Full Text] [Related]
2. Computer-based de novo design of drug-like molecules.
Schneider G; Fechner U
Nat Rev Drug Discov; 2005 Aug; 4(8):649-63. PubMed ID: 16056391
[TBL] [Abstract][Full Text] [Related]
3. Affinity-based screening techniques for enhancing lead discovery.
Comess KM; Schurdak ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
[TBL] [Abstract][Full Text] [Related]
4. Hit and Lead identification: efficient practices for drug discovery.
Goodnow RA; Gillespie P
Prog Med Chem; 2007; 45():1-61. PubMed ID: 17280901
[No Abstract] [Full Text] [Related]
5. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads.
Langer T; Krovat EM
Curr Opin Drug Discov Devel; 2003 May; 6(3):370-6. PubMed ID: 12833670
[TBL] [Abstract][Full Text] [Related]
6. Towards improving compound selection in structure-based virtual screening.
Waszkowycz B
Drug Discov Today; 2008 Mar; 13(5-6):219-26. PubMed ID: 18342797
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based drug design: combining philosophy with technology.
Bartoli S; Fincham CI; Fattori D
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483
[TBL] [Abstract][Full Text] [Related]
8. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
9. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in de novo design and scaffold hopping.
Mauser H; Guba W
Curr Opin Drug Discov Devel; 2008 May; 11(3):365-74. PubMed ID: 18428090
[TBL] [Abstract][Full Text] [Related]
11. The hit-to-lead process at Schering AG: strategic aspects.
Steinmeyer A
ChemMedChem; 2006 Jan; 1(1):31-6. PubMed ID: 16892330
[TBL] [Abstract][Full Text] [Related]
12. Hit finding: towards 'smarter' approaches.
Langer T; Hoffmann R; Bryant S; Lesur B
Curr Opin Pharmacol; 2009 Oct; 9(5):589-93. PubMed ID: 19576852
[TBL] [Abstract][Full Text] [Related]
13. HTS technologies in biopharmaceutical discovery.
Wu G; Doberstein SK
Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799
[TBL] [Abstract][Full Text] [Related]
14. Structure-based drug metabolism predictions for drug design.
Sun H; Scott DO
Chem Biol Drug Des; 2010 Jan; 75(1):3-17. PubMed ID: 19878193
[TBL] [Abstract][Full Text] [Related]
15. A review of high throughput technology for the screening of natural products.
Mishra KP; Ganju L; Sairam M; Banerjee PK; Sawhney RC
Biomed Pharmacother; 2008 Feb; 62(2):94-8. PubMed ID: 17692498
[TBL] [Abstract][Full Text] [Related]
16. The synergy between combinatorial chemistry and high-throughput screening.
Diller DJ
Curr Opin Drug Discov Devel; 2008 May; 11(3):346-55. PubMed ID: 18428088
[TBL] [Abstract][Full Text] [Related]
17. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example.
Rollinger JM; Haupt S; Stuppner H; Langer T
J Chem Inf Comput Sci; 2004; 44(2):480-8. PubMed ID: 15032527
[TBL] [Abstract][Full Text] [Related]
18. Protein biochips: the calm before the storm.
Bodovitz S; Joos T; Bachmann J
Drug Discov Today; 2005 Feb; 10(4):283-7. PubMed ID: 15708747
[TBL] [Abstract][Full Text] [Related]
19. Synthetic library design.
Huwe CM
Drug Discov Today; 2006 Aug; 11(15-16):763-7. PubMed ID: 16846805
[TBL] [Abstract][Full Text] [Related]
20. Which aspects of HTS are empirically correlated with downstream success?
Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
